Risk of fracture after androgen deprivation for prostate cancer
Risk of fracture after androgen deprivation for prostate cancer
复制标题
DOI：
10.1056/nejmoa041943
复制
发表时间：
2005-01-13
影响因子：
158.5
通讯作者：
Goodwin, JS
中科院分区：
文献类型：
--
作者：
Shahinian, VB;Kuo, Y;Goodwin, JS
背景：在过去的15年中，雄激素剥夺疗法在前列腺癌中的应用大幅增加。这种治疗与骨矿物质密度的损失有关，但雄激素剥夺治疗后骨折的风险尚未得到很好的study.Methods：我们研究了50,613名男性的记录，这些男性在1992年至1997年期间被诊断为前列腺癌，并被列入监测、流行病学和最终结果项目和医疗保险的链接数据库。主要结局是发生任何骨折和发生导致住院的骨折。考克斯比例风险分析根据患者和癌症的特征、接受的其他癌症治疗以及在癌症诊断前12个月内骨折或骨质疏松症的诊断进行调整。在确诊后存活至少5年的男性中，接受雄激素剥夺治疗的患者中有19.4%发生骨折，与未接受雄激素剥夺治疗的12.6%相比，
Background: The use of androgen-deprivation therapy for prostate cancer has increased substantially over the past 15 years. This treatment is associated with a loss of bone-mineral density, but the risk of fracture after androgen-deprivation therapy has not been well studied.Methods: We studied the records of 50,613 men who were listed in the linked database of the Surveillance, Epidemiology, and End Results program and Medicare as having received a diagnosis of prostate cancer in the period from 1992 through 1997. The primary outcomes were the occurrence of any fracture and the occurrence of a fracture resulting in hospitalization. Cox proportional-hazards analyses were adjusted for characteristics of the patients and the cancer, other cancer treatment received, and the occurrence of a fracture or the diagnosis of osteoporosis during the 12 months preceding the diagnosis of cancer.Results: Of men surviving at least five years after diagnosis, 19.4 percent of those who received androgen-deprivation therapy had a fracture, as compared with 12.6 percent of those not receiving androgen-deprivation therapy (P